Tech Company Financing Transactions
CytomX Therapeutics Funding Round
Canaan Partners, Roche Venture Fund and Third Rock Ventures invested in a $31 million Series B funding round for CytomX Therapeutics. The financing closed on 7/31/2012.
Transaction Overview
Company Name
Announced On
7/31/2012
Transaction Type
Venture Equity
Amount
$31,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds from the expanded Series B financing round will support the advancement of the company's lead programs toward the clinic and the execution on broad business development activities aimed at the formation of key partnerships in oncology and inflammatory disease.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
151 Oyster Point Blvd. 400
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
CytomX (NASDAQ: CTMX) is unlocking the potential of antibody therapeutics in oncology by developing a novel therapeutic antibody class of highly targeted Probody therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sean McCarthy
Chief Scientific Officer
Michael Kavanaugh
Vice President
Alison Joly
VP - Human Resources
Danielle Olander
VP - Manufacturing
Sridhar Viswanathan
Browse more venture capital transactions:
Prev: 7/31/2012: TrueVision Systems venture capital transaction
Next: 7/31/2012: 9GAG venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on all VC transactions involving tech companies. VC investment data records on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs